Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF‐1α‐mediated glycolysis

Yoon Mi Lee, Geon Hee Kim, Eun Ji Park, Taek In Oh, Sujin Lee, Sang Yeon Kan, Hyeji Kang, Byeong Mo Kim, Ji Hyung Kim, Ji Hong Lim

Research output: Contribution to journalArticle

Abstract

Several reports have shown that thymoquinone (TQ) effectively attenuates angiogenesis in cancer cells, resulting in suppression of tumor growth. However, it is not yet clear whether TQ reduces hypoxia‐inducible factor‐1α (HIF‐1α) expression in hypoxic cancer cells. Here, we found that TQ was a novel HIF‐1α inhibitor through hypoxia response element (HRE)‐luciferase assay-based large screening by using 502 natural compounds containing chemical library. TQ reduced HIF‐1α protein levels in renal cancer cells; however, it did not affect the HIF‐1α protein levels in the presence of proteasome inhibitor, MG132, indicating that the reduction effects of TQ on HIF‐1α protein are mediated via the ubiquitination‐proteasome dependent pathway. TQ boosted HIF‐1α protein degradation, and the mechanism was revealed by inhibiting interaction between HSP90 and HIF‐1α. TQ suppressed downstream genes of HIF‐1α, indicating negative impact of TQ on HIF‐1α transcriptional activities. In addition, TQ altered glucose, lactate, and ATP levels, leading to anaerobic metabolic disturbance. TQ induced apoptosis in hypoxic cancer cells as determined by crystal violet staining and flow cytometry for annexin V‐stained cells. Taken together, we suggested that TQ is a potential anticancer agent targeting HIF‐1α.

Original languageEnglish
Article number1092
JournalInternational journal of molecular sciences
Volume20
Issue number5
DOIs
Publication statusPublished - 2019 Mar 1

Fingerprint

glycolysis
Glycolysis
Renal Cell Carcinoma
cancer
Cells
proteins
Proteins
inhibitors
angiogenesis
chemical compounds
lactates
cytometry
Flow cytometry
adenosine triphosphate
Adenosinetriphosphate
hypoxia
apoptosis
staining
Cell death
glucose

Keywords

  • Glycolysis
  • HIF‐1α
  • Renal cancer
  • Thymoquinone

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF‐1α‐mediated glycolysis. / Lee, Yoon Mi; Kim, Geon Hee; Park, Eun Ji; Oh, Taek In; Lee, Sujin; Kan, Sang Yeon; Kang, Hyeji; Kim, Byeong Mo; Kim, Ji Hyung; Lim, Ji Hong.

In: International journal of molecular sciences, Vol. 20, No. 5, 1092, 01.03.2019.

Research output: Contribution to journalArticle

Lee, Yoon Mi ; Kim, Geon Hee ; Park, Eun Ji ; Oh, Taek In ; Lee, Sujin ; Kan, Sang Yeon ; Kang, Hyeji ; Kim, Byeong Mo ; Kim, Ji Hyung ; Lim, Ji Hong. / Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF‐1α‐mediated glycolysis. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 5.
@article{9527a03df7d641fb9a7c62d3f15b5669,
title = "Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF‐1α‐mediated glycolysis",
abstract = "Several reports have shown that thymoquinone (TQ) effectively attenuates angiogenesis in cancer cells, resulting in suppression of tumor growth. However, it is not yet clear whether TQ reduces hypoxia‐inducible factor‐1α (HIF‐1α) expression in hypoxic cancer cells. Here, we found that TQ was a novel HIF‐1α inhibitor through hypoxia response element (HRE)‐luciferase assay-based large screening by using 502 natural compounds containing chemical library. TQ reduced HIF‐1α protein levels in renal cancer cells; however, it did not affect the HIF‐1α protein levels in the presence of proteasome inhibitor, MG132, indicating that the reduction effects of TQ on HIF‐1α protein are mediated via the ubiquitination‐proteasome dependent pathway. TQ boosted HIF‐1α protein degradation, and the mechanism was revealed by inhibiting interaction between HSP90 and HIF‐1α. TQ suppressed downstream genes of HIF‐1α, indicating negative impact of TQ on HIF‐1α transcriptional activities. In addition, TQ altered glucose, lactate, and ATP levels, leading to anaerobic metabolic disturbance. TQ induced apoptosis in hypoxic cancer cells as determined by crystal violet staining and flow cytometry for annexin V‐stained cells. Taken together, we suggested that TQ is a potential anticancer agent targeting HIF‐1α.",
keywords = "Glycolysis, HIF‐1α, Renal cancer, Thymoquinone",
author = "Lee, {Yoon Mi} and Kim, {Geon Hee} and Park, {Eun Ji} and Oh, {Taek In} and Sujin Lee and Kan, {Sang Yeon} and Hyeji Kang and Kim, {Byeong Mo} and Kim, {Ji Hyung} and Lim, {Ji Hong}",
year = "2019",
month = "3",
day = "1",
doi = "10.3390/ijms20051092",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF‐1α‐mediated glycolysis

AU - Lee, Yoon Mi

AU - Kim, Geon Hee

AU - Park, Eun Ji

AU - Oh, Taek In

AU - Lee, Sujin

AU - Kan, Sang Yeon

AU - Kang, Hyeji

AU - Kim, Byeong Mo

AU - Kim, Ji Hyung

AU - Lim, Ji Hong

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Several reports have shown that thymoquinone (TQ) effectively attenuates angiogenesis in cancer cells, resulting in suppression of tumor growth. However, it is not yet clear whether TQ reduces hypoxia‐inducible factor‐1α (HIF‐1α) expression in hypoxic cancer cells. Here, we found that TQ was a novel HIF‐1α inhibitor through hypoxia response element (HRE)‐luciferase assay-based large screening by using 502 natural compounds containing chemical library. TQ reduced HIF‐1α protein levels in renal cancer cells; however, it did not affect the HIF‐1α protein levels in the presence of proteasome inhibitor, MG132, indicating that the reduction effects of TQ on HIF‐1α protein are mediated via the ubiquitination‐proteasome dependent pathway. TQ boosted HIF‐1α protein degradation, and the mechanism was revealed by inhibiting interaction between HSP90 and HIF‐1α. TQ suppressed downstream genes of HIF‐1α, indicating negative impact of TQ on HIF‐1α transcriptional activities. In addition, TQ altered glucose, lactate, and ATP levels, leading to anaerobic metabolic disturbance. TQ induced apoptosis in hypoxic cancer cells as determined by crystal violet staining and flow cytometry for annexin V‐stained cells. Taken together, we suggested that TQ is a potential anticancer agent targeting HIF‐1α.

AB - Several reports have shown that thymoquinone (TQ) effectively attenuates angiogenesis in cancer cells, resulting in suppression of tumor growth. However, it is not yet clear whether TQ reduces hypoxia‐inducible factor‐1α (HIF‐1α) expression in hypoxic cancer cells. Here, we found that TQ was a novel HIF‐1α inhibitor through hypoxia response element (HRE)‐luciferase assay-based large screening by using 502 natural compounds containing chemical library. TQ reduced HIF‐1α protein levels in renal cancer cells; however, it did not affect the HIF‐1α protein levels in the presence of proteasome inhibitor, MG132, indicating that the reduction effects of TQ on HIF‐1α protein are mediated via the ubiquitination‐proteasome dependent pathway. TQ boosted HIF‐1α protein degradation, and the mechanism was revealed by inhibiting interaction between HSP90 and HIF‐1α. TQ suppressed downstream genes of HIF‐1α, indicating negative impact of TQ on HIF‐1α transcriptional activities. In addition, TQ altered glucose, lactate, and ATP levels, leading to anaerobic metabolic disturbance. TQ induced apoptosis in hypoxic cancer cells as determined by crystal violet staining and flow cytometry for annexin V‐stained cells. Taken together, we suggested that TQ is a potential anticancer agent targeting HIF‐1α.

KW - Glycolysis

KW - HIF‐1α

KW - Renal cancer

KW - Thymoquinone

UR - http://www.scopus.com/inward/record.url?scp=85062421871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062421871&partnerID=8YFLogxK

U2 - 10.3390/ijms20051092

DO - 10.3390/ijms20051092

M3 - Article

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 5

M1 - 1092

ER -